151 related articles for article (PubMed ID: 15846660)
1. Single agent versus combination chemotherapy for metastatic breast cancer.
Carrick S; Parker S; Wilcken N; Ghersi D; Marzo M; Simes J
Cochrane Database Syst Rev; 2005 Apr; (2):CD003372. PubMed ID: 15846660
[TBL] [Abstract][Full Text] [Related]
2. WITHDRAWN: Multi-agent chemotherapy for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000487. PubMed ID: 18843612
[TBL] [Abstract][Full Text] [Related]
3. Estimating the Time Toxicity of Contemporary Systemic Treatment Regimens for Advanced Esophageal and Gastric Cancers.
Agrawal NY; Thawani R; Edmondson CP; Chen EY
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067380
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity.
Foster J; Freidlin B; Korn EL; Smith M
ESMO Open; 2020 Oct; 5(5):e000871. PubMed ID: 33122353
[TBL] [Abstract][Full Text] [Related]
5. Estimation of US patients with cancer who may respond to cytotoxic chemotherapy.
Maldonado EB; Parsons S; Chen EY; Haslam A; Prasad V
Future Sci OA; 2020 May; 6(8):FSO600. PubMed ID: 32983564
[TBL] [Abstract][Full Text] [Related]
6. Response to response to letter entitled: Re: Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Guennebaud B; Rivoire A
Eur J Cancer; 2023 Nov; 193():113279. PubMed ID: 37678104
[No Abstract] [Full Text] [Related]
7. Single agent versus combination chemotherapy for metastatic breast cancer.
Carrick S; Parker S; Thornton CE; Ghersi D; Simes J; Wilcken N
Cochrane Database Syst Rev; 2009 Apr; 2009(2):CD003372. PubMed ID: 19370586
[TBL] [Abstract][Full Text] [Related]
8. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.
Gennari A; Stockler M; Puntoni M; Sormani M; Nanni O; Amadori D; Wilcken N; D'Amico M; DeCensi A; Bruzzi P
J Clin Oncol; 2011 Jun; 29(16):2144-9. PubMed ID: 21464403
[TBL] [Abstract][Full Text] [Related]
9. Combination versus sequential single agent chemotherapy for metastatic breast cancer.
Dear RF; McGeechan K; Jenkins MC; Barratt A; Tattersall MH; Wilcken N
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008792. PubMed ID: 24347031
[TBL] [Abstract][Full Text] [Related]
10. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Mauri D; Pavlidis N; Polyzos NP; Ioannidis JP
J Natl Cancer Inst; 2006 Sep; 98(18):1285-91. PubMed ID: 16985247
[TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
Taylor CW; Green S; Dalton WS; Martino S; Rector D; Ingle JN; Robert NJ; Budd GT; Paradelo JC; Natale RB; Bearden JD; Mailliard JA; Osborne CK
J Clin Oncol; 1998 Mar; 16(3):994-9. PubMed ID: 9508182
[TBL] [Abstract][Full Text] [Related]
12. Role of surgery in the treatment of brain metastases in patients with breast cancer.
Pieper DR; Hess KR; Sawaya RE
Ann Surg Oncol; 1997 Sep; 4(6):481-90. PubMed ID: 9309337
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial.
Cameron D; Casey M; Oliva C; Newstat B; Imwalle B; Geyer CE
Oncologist; 2010; 15(9):924-34. PubMed ID: 20736298
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson L; Lawrence D; Dawson C; Bliss J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD003370. PubMed ID: 19821307
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
Baselga J; Cortés J; Kim SB; Im SA; Hegg R; Im YH; Roman L; Pedrini JL; Pienkowski T; Knott A; Clark E; Benyunes MC; Ross G; Swain SM;
N Engl J Med; 2012 Jan; 366(2):109-19. PubMed ID: 22149875
[TBL] [Abstract][Full Text] [Related]
16. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.
Robert NJ; Diéras V; Glaspy J; Brufsky AM; Bondarenko I; Lipatov ON; Perez EA; Yardley DA; Chan SY; Zhou X; Phan SC; O'Shaughnessy J
J Clin Oncol; 2011 Apr; 29(10):1252-60. PubMed ID: 21383283
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
von Minckwitz G; du Bois A; Schmidt M; Maass N; Cufer T; de Jongh FE; Maartense E; Zielinski C; Kaufmann M; Bauer W; Baumann KH; Clemens MR; Duerr R; Uleer C; Andersson M; Stein RC; Nekljudova V; Loibl S
J Clin Oncol; 2009 Apr; 27(12):1999-2006. PubMed ID: 19289619
[TBL] [Abstract][Full Text] [Related]
18. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
19. Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.
Kurian AW; Gong GD; John EM; Miron A; Felberg A; Phipps AI; West DW; Whittemore AS
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1084-91. PubMed ID: 19336551
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
